PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function by Sincock, P. M. et al.
INTRODUCTION
The vascular endothelium provides a dynamic non-
thrombogenic barrier between the bloodstream and
extravascular tissues. The cellular interactions required for the
maintenance and function of the vascular endothelium are
tightly regulated and are mediated through soluble factors and
adhesion molecules. Members of one such family of adhesion
molecules, the integrins, are involved in cell-matrix and cell-
cell adhesive events through their interaction with the
cytoskeleton. Integrins are comprised of heterodimers of an a
and b chain and it is the association of these chains which
defines ligand specificity (reviewed by Schwartz et al., 1995).
Cultured endothelial cells (EC) express many integrins
including several of the b 1 subfamily, a vb 3, a 6b 4, a vb 5 and
these molecules are involved in many aspects of endothelial
function including vasculogenesis, angiogenesis, wound
healing, recruitment of leukocytes to sites of inflammation and
regulation of thrombosis (reviewed by Shattil and Ginsberg,
1997).
Previously, we described the cloning of PETA-3 (Fitter et
al., 1995), a member of the transmembrane 4 superfamily
(TM4SF) (reviewed by Wright and Tomlinson, 1994; Maecker
et al., 1997), which was assigned CD151 at the VIth
International Leucocyte Typing workshop (Ashman et al.,
1997). Subsequently, PETA-3 was independently cloned from
the adult T cell leukaemia cell line, SF-HT, and termed SFA-
1 (SF-HT-activated gene 1) (Hasegawa et al., 1996).
Immunohistochemical studies have demonstrated expression
of PETA-3 by epithelium, muscle, Schwann cells and
ubiquitous expression by endothelium in vivo. Within
haemopoietic cells, PETA-3 is mostly restricted to platelets and
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The Transmembrane 4 Superfamily member, PETA-
3/CD151, is ubiquitously expressed by endothelial cells in
vivo. In cultured human umbilical vein endothelial cells
PETA-3 is present on the plasma membrane and
predominantly localises to regions of cell-cell contact.
Additionally, this protein is abundant within an
intracellular compartment which accounts for up to 66%
of the total PETA-3 expressed. Intracellular PETA-3
showed colocalisation with transferrin receptor and CD63
suggesting an endosomal/lysosomal localisation which was
supported by immuno-electronmicroscopy studies. Co-
immunoprecipitation experiments investigating possible
interactions of PETA-3 with other molecules demonstrated
associations with several integrin chains including b 1, b 3,
b 4, a 2, a 3, a 5, a 6 and provide the first report of
Transmembrane 4 Superfamily association with the a 6b 4
integrin. Using 2-colour confocal microscopy, we
demonstrated similar localisation of PETA-3 and integrin
chains within cytoplasmic vesicles and endothelial cell
junctions. In order to assess the functional implications of
PETA-3/integrin associations, the effect of anti-PETA-3
antibodies on endothelial function was examined. Anti-
PETA-3 mAb inhibited endothelial cell migration and
modulated in vitro angiogenesis, but had no detectable
effect on neutrophil transendothelial migration. The 
broad range of integrin associations and the presence of
PETA-3 with integrins both on the plasma membrane and
within intracellular vesicles, suggests a primary role for
PETA-3 in regulating integrin trafficking and/or function.
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megakaryocytes (Sincock et al., 1997; Ashman et al., 1991)
where it may be involved in recognition of subendothelial
matrix during thrombus formation and in thrombopoiesis,
respectively.
Recent studies have demonstrated that PETA-3 is localised
to endothelial cell junctions and have suggested that complexes
of PETA-3 and a 3b 1 integrin modulate endothelial cell
motility (Yanez-Mo et al., 1998). Several other members of the
TM4SF, notably CD9, CD63, CD81 and CD82 have also been
demonstrated to associate with integrins of the b 1 subfamily
including a 3b 1 (Berditchevski et al., 1995, 1996; Nakamura et
al., 1995; Hadjiargyrou et al., 1996), a 4b 1 (Rubinstein et al.,
1994; Mannion et al., 1996) and a 6b 1 (Berditchevski et al.,
1995, 1996; Hadjiargyrou et al., 1996; reviewed by Porter and
Hogg, 1998; Hemler et al., 1996). Furthermore, monoclonal
antibodies (mAbs) against CD9 and CD81 have been shown to
modulate cellular motility and adhesion (reviewed by Maecker
et al., 1997).
The abundant expression of PETA-3 in EC, its association
with b 1 integrins, the induction of homotypic adhesion in
haemopoietic cell lines by PETA-3 mAbs (Fitter et al., 1999)
and the recent finding that phosphatidylinositol-4 kinase (PI4-
K) associates with this molecule (Yauch et al., 1998) suggest
a possible role for PETA-3 in the regulation of integrin function
in EC. This study examines the subcellular localisation of
PETA-3, further characterises the association of a broader
range of integrin molecules, and examines functional aspects
of PETA-3/integrin complexes in cultured human umbilical
vein endothelial cells (HUVEC). Additionally we report the
novel finding that the majority of PETA-3 resides within an
intracellular endosomal/lysosomal compartment and propose
that this molecule may be involved in integrin transport and/or
turnover from the plasma membrane.
MATERIALS AND METHODS
Cell culture
HUVEC were isolated by collagenase treatment of umbilical veins,
as previously described (Wall et al., 1978). Cells were maintained in
M199 medium supplemented with Earle’s salts (Cytosystems, Sydney,
Australia), 20% foetal bovine serum, 20 mM Hepes, 2 mM glutamine,
1% non-essential amino acids, 1 mM sodium pyruvate (Cytosystems),
0.225% sodium bicarbonate, antibiotics (penicillin and gentamycin),
20 m g/ml heparin, (Sigma, St Louis, MO), and 20 m g/ml endothelial
cell growth supplement (Collaborative Biomedical Products, Bedford,
MA) (EC medium). EC were cultured in gelatin-coated tissue culture
flasks and passaged when confluent by detachment with
trypsin/EDTA (Cytosystems). Passage 1 to 4 cells were used for
experiments.
Antibodies
The anti-PETA-3 mAbs 11B1.G4 and 14A2.H1, anti-CD9 mAb,
1AA2.H9, anti-CD63 mAb, 12F12, anti-b 1 integrin mAb 61-2C4 and
anti-PECAM-1 mAb B2B1 have been described previously (Sincock
et al., 1997; Ashman et al., 1997; Cole et al., 1989). Other mAbs were
obtained as follows; anti-b 1 integrin mAb 8A2 (Kovach et al., 1992)
was kindly provided by Dr N. Kovak (University of Washington, WA),
anti-a 2 16B4 (Serotec, Oxford, UK); anti-a 3, P1B5 (Gibco BRL,
Gaithersburg MD); anti-a 5, PHM2 (Becker et al., 1981), provided
courtesy of Dr R. Faull (Royal Adelaide Hospital, Australia); anti-a 6,
GoH3 (PharMingen, San Diego, CA); anti-b 3, AP-3 (ATCC,
Rockville, MD) and anti-b 4 439-9B (PharMingen). The anti-
transferrin receptor mAb OKT-9 was obtained from the ATCC, anti-g -
adaptin mAb 100/3 was purchased from Sigma and anti-p180 (Savitz
and Meyer, 1990) rabbit polyclonal antiserum was the generous gift of
Dr P. Meyer (University of California and Los Angeles, CA). The anti-
CD44, mAb H9H11 (unpublished), was provided by Dr P. Simmons
(Hanson Centre for Cancer Research), anti-CD34 mAb, 561
(unpublished) provided courtesy of Dr G. Gaudinack (The National
Hospital, Oslo, Norway), anti-von Willebrand factor mAb, 49-5C3 (J.
Gamble, unpublished) and anti-VE-cadherin mAb, 55-7H1 (Martin-
Padura et al., 1997) provided by Dr L. Wayner (University of
Minnesota, Minneapolis, MI). Rabbit polyclonal anti-PETA-3
antibody was raised against PETA-3 purified from platelets as
described (Fitter et al., 1995). The specificity of this reagent was
verified by analysis of binding to PETA-3, CD63 and CD9
transfectants, and by western blotting studies. Isotype matched non-
binding mAbs 1B5 (IgG1) and 1D4.5 (IgG2a) (Sincock et al., 1997)
or normal rabbit serum (NRS) were included in all experiments as
specificity controls. For isotype matched binding controls, 3D2 (IgG1)
anti-PECAM-1 and 61-2A1 (IgG2a) anti-E-selectin were used.
Indirect immunofluorescence labelling
For confocal microscopy, cells were plated at 5 · 104 per well in
chamber slides (Lab Tek, Nunc, Roskilde, Denmark) precoated with
50 m g fibronectin (Boehringer Mannheim, Mannheim, Germany)
and grown to various degrees of confluence over 2-4 days. Cells
were fixed (47.5% acetone, 47.5% methanol, 5% formaldehyde) for
30 seconds on ice. For non-permeabilising fixation, cells were fixed
with 2% formaldehyde for 5 minutes on ice. After washing, cells
were incubated with primary mAb supplemented with 10% NRS and
0.1% azide for 45 minutes on ice. Cells were then washed and
incubated with rabbit anti-mouse Ig FITC (AMRAD, Melbourne,
Australia) for 45 minutes on ice. For 2-colour labelling, cells were
incubated with both primary mAbs, washed then incubated with goat
anti-mouse IgG1 Tri-Color (Caltag, San Francisco, CA) and anti-
IgG2a FITC, (Caltag), supplemented as above. For wheatgerm
agglutinin (WGA) staining, cells were incubated with 5 m g/ml
biotinylated WGA, washed and incubated with streptavidin-Tri-
Color (Caltag). After labelling, cells were washed, fixed with 1%
paraformaldehyde and mounted in 86% glycerol containing 1%
propyl-gallate (Sigma). Confocal microscopy was performed using
a MRC 600 confocal microscope (Bio-Rad, Hercules, CA). Isotype
matched negative control mAbs or normal rabbit serum were
included in all indirect immunofluorescence labelling experiments
as specificity controls.
Quantitation of intracellular antigens was performed using flow
cytometry and saponin permeabilisation as previously described
(Fitter et al., 1999). Briefly, cells were harvested with 1 mM EDTA,
washed in cold wash buffer (PBS, pH 7.4, 0.1% BSA, 0.1% azide)
and fixed with 2% formaldehyde for 10 minutes at room temperature.
Cells were labelled by indirect immunofluorescence and bound mAb
was detected by incubation with r-phycoerythrin-conjugated goat anti-
mouse immunoglobulin (Caltag). mAb binding was quantitated by a
Coulter (Hialeah, FL) EPICS XL flow cytometer. Percentage
intracellular antigen was calculated by comparison of the mean
fluorescence intensity of labelled formaldehyde fixed cells with
formaldehyde fixed saponin permeabilised cells after correction for
isotype match negative control binding.
Electron microscopy
EC monolayers were fixed with 8% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.35, for 1 hour at room temperature. Cells were
then washed with 0.2 M phosphate buffer, scraped from the culture
dish and pelleted at 8,000 g. The cells were then resuspended in warm
gelatin (10% in phosphate buffer) and repelleted. After cooling,
gelatin-embedded cells were infiltrated with PVP-sucrose overnight
at 4°C and processed for frozen sectioning as described previously
(Parton et al., 1997). Ultrathin frozen sections (60-80 nm) were
labelled, stained, and viewed (Jeol 1010, Centre for Microscopy and
P. M. Sincock and others
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Microanalysis, University of Queensland) according to published
techniques (Parton et al., 1997).
Immunoprecipitation and western blotting
EC were lysed with CHAPS lysis buffer (1% CHAPS; Sigma), 10 mM
Tris-HCl, pH 7.4, 140 mM NaCl, 0.5 mM CaCl2, 0.5 mM MgCl2 and
containing 40 m g/ml each of PMSF, TPCK, TLCK and p-nitrophenyl-
p¢ -guanidino-benzoate-HCl, all from Sigma) for 30 minutes on ice.
Alternatively 1% NP-40 buffer (1% NP-40, Fluka (Buchs,
Switzerland), 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA,
supplemented as above) was used for some experiments as indicated.
Specific molecules were immunoprecipitated by incubation of lysate
from 107 cells with 2-5 m g of purified antibody and goat anti-mouse
immunoglobulin-Sepharose for 2 hours at 4°C. A cocktail of isotype
matched negative control mAbs 1D4.5 and 3D3.3 was included
in all immunoprecipitation experiments as specificity control.
Immunoprecipitates were washed four times in 1% lysis buffer
followed by one wash in 0.1% lysis buffer, eluted with SDS-PAGE
loading buffer at 100°C for 4 minutes and separated on 12% PAGE
gels under non-reduced conditions. Proteins were electroblotted to
polyvinyl difluoride (PVDF) membrane (Micron Separations Inc.,
Westborough, MA), then blots were washed in Tris buffered saline
supplemented with 0.1% Tween-20 (TBST). Detection of PETA-3
was performed by incubation with biotinylated 11B1.G4 in TBST for
2 hours. After washing, bound primary antibody was detected using
streptavidin-alkaline phosphatase (Molecular Probes, Eugene, OR)
and visualised using the VISTRA ECF substrate (Amersham,
Buckinghamshire, UK) and a FluorImager 595 (Molecular Dynamics,
Sunnyvale, CA).
For re-precipitation experiments EC were surface labelled with 0.5
mg/ml Sulfo-NHS-Biotin (Pierce, Rockford, IL) for 30 minutes at
room temperature. Unreacted biotin was washed from the cells before
addition of CHAPS lysis buffer. Immunoprecipitation with the anti-
PETA-3 mAb 11B1.G4 was then carried out as described. 11B1.G4
immunoprecipitates were washed as above then eluted in 1% NP-40
supplemented with 0.2% SDS for 2 hours at 4°C. Eluted proteins were
diluted 1:2 in NP-40 buffer, then reprecipitated as described above.
Reprecipitated proteins were washed twice in NP-40 buffer before
separation on 12% SDS-PAGE gels under reduced conditions. After
transfer to PVDF membrane, labelled proteins were detected with
streptavidin-alkaline phosphatase and visualised as described.
Motility assay
Third passage ECs were aliquotted into gelatin coated 6 well plates
at 5· 105 per well. After culture for 3 days, confluent monolayers were
‘wounded’ with a 4 mm latex scraper and the edge of the wounds
marked. Monolayers were immediately washed to remove debris and
complete EC medium with or without mAbs (1-10 m g/ml), as
indicated, was added. Five randomly selected points along each
wound were marked and the horizontal distance of migrating cells
from the initial wound was measured at the times indicated using · 200
magnification with a 50 m m grid in the eyepiece. For each timepoint,
measurements were taken from duplicate wells with three wounds per
well. In order to determine whether mAb-induced proliferation
contributed to the movement of cells into the wound, total protein
content of all wells was measured. At the conclusion of the
experiment, wells were washed twice with cold PBS and the cells
lysed with 1% NP-40 for 2 hours on ice. Total protein content of all
lysates was then measured, using a Bradford Protein Determination
Kit (Bio-Rad) in accordance with the manufacturer’s instructions.
In vitro angiogenesis assay
Matrigel (Collaborative Biomedical Products) was diluted 1:1.5 in cold
serum free M199 medium supplemented as described above, with the
omission of EC growth factors and heparin. Aliquots (100 m l) were
plated into flat bottomed 96-well microtitre plates and allowed to gel
for 1-2 hours at 37°C. EC were then plated into each well at a
concentration of 2.5· 104/well in 150 m l volume of complete EC
medium supplemented with 1-10 m g/ml mAb as indicated. Capillary
tubes were defined as cellular extensions linking cell masses or branch
points and were quantitated from photographs of duplicate wells at 10
and 20 hours time points. Both tube length and number of tubes were
quantitated. Statistical analysis of pooled data from three experiments
was performed by 2-tailed t-tests for both tube length and number. mAb
treatments were compared to both untreated and isotype matched non-
binding controls for each time point (P<0.05 was considered
statistically significant).
RESULTS
PETA-3 is localised to perinuclear vesicles and
endothelial cell junctions
Preliminary flow cytometric studies to investigate the
expression of TM4SF members and integrins by cultured EC
were carried out. Antibodies against TM4SF proteins varied in
their level of surface binding with very strong staining of CD9,
strong PETA-3, and low staining of CD63. Binding of the anti-
b 1 mAb, 2C4 was the highest of the b chains examined, with
lower levels of b 3 and b 4 detected. Expression of a 2 and a 6
were also high, with lower a 3 and a 5 levels detected. The a 4
chain was not detected (data not shown).
The cellular distribution of PETA-3 in EC was investigated
by indirect immunofluorescence and confocal microscopy. In
formaldehyde-fixed confluent EC monolayers, anti-PETA-3
mAb strongly stained regions of cell-cell contact (Fig. 1A) as
previously described (Yanez-Mo et al., 1998). However, upon
permeabilisation, PETA-3 stained the perinuclear region in
addition to cellular margins (Fig. 1B). At low culture density,
PETA-3 showed stronger, more diffuse staining of the
perinuclear region (Fig. 1C). Although staining of the plasma
membrane at low culture density was diffuse, concentration of
PETA-3 in regions of cell-cell contact was still apparent.
Staining for CD9 showed a similar junctional distribution to
PETA-3, however, no intracellular staining was observed in
permeabilised cells (Fig. 1D). The distribution of intracellular
PETA-3 differed from that of the endoplasmic reticulum
marker, gp180 (Savitz and Meyer, 1990), which appeared as a
diffuse network extending to the periphery of the cell (Fig. 1E).
Since PETA-3 staining did not resemble the endoplasmic
reticulum, the possibility of an endosomal/Golgi localisation
was examined. Consistent with this, staining of low density
ECs with WGA, which binds the Golgi-apparatus, endosomes
and plasma membrane (Tartakoff and Vassalli 1983), displayed
a perinuclear morphology strongly resembling PETA-3 (Fig.
1F). Furthermore 2-colour staining for PETA-3 and WGA
showed strong intracellular colocalisation (data not shown).
In order to quantitate the level of intracellular PETA-3, ECs
were labelled by indirect immunofluorescence in the presence
and absence of the permeabilising agent saponin, and analysed
by flow cytometry (Fig. 2). PETA-3 staining was enhanced
approximately 3-fold in saponin treated cells, indicating that
the intracellular pool comprised approximately 66% of the total
PETA-3 expressed (Fig. 2A). In contrast, no intracellular CD9
was detected (Fig. 2B), whilst approximately 85% of CD63
was found to be intracellular (Fig. 2C). The detection of
intracellular antigens by saponin permeabilisation was
consistent with that observed by confocal microscopy (see Fig.
1C,D, and below).
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The level of surface expression or subcellular distribution of
PETA-3 were not modulated by treatment of EC with tumour
necrosis factor-a , interferon-g , vascular endothelial growth
factor and basic-fibroblast growth factor despite upregulation
of E-selectin and ICAM-1 after 6 and 48 hours post-treatment,
respectively (data not shown).
Intracellular PETA-3 resides within an endosomal
compartment
To further characterise the intracellular compartment in which
PETA-3 resides, 2-colour colocalisation studies were carried
out. The morphology of the Golgi apparatus, as determined by
staining with mAb against g -adaptin (Robinson and Pearse,
1986), did not correspond with PETA-3 suggesting that the
majority of PETA-3 does not reside within this compartment
(Fig. 3A,B,C). Furthermore treatment with brefeldin A
(Fujiwara et al., 1988) for 10 minutes failed to alter the
localisation of PETA-3, although redistribution of g -adaptin
from the Golgi was observed (data not shown). Staining of
Weibel-Palade bodies for von Willebrand factor (Ewenstein et
al., 1987) failed to significantly colocalise with PETA-3 (Fig.
3D,E,F). In contrast, intracellular transferrin receptor, which is
present in the early sorting endosome and the perinuclear early
recycling endosome (Gruenberg and Maxfield, 1995), showed
some colocalisation with PETA-3, especially within the
perinuclear region (Fig. 3G,H,I). CD63, which is present in
lysosomes and Weibel-Palade bodies (Metzelaar et al., 1991),
showed strong colocalisation with PETA-3 in the perinuclear
region (Fig. 3J,K,L).
PETA-3 is localised to endosomal structures by
immuno-electron microscopy
Due to the limited resolution of confocal analysis, the
distribution of PETA-3 was further examined at the
ultrastructural level using anti-PETA-3 antibodies on ultrathin
frozen sections of EC. Similar labelling was observed with four
different antibody preparations; affinity purified anti-PETA-3
rabbit polyclonal (100 m g/ml), rabbit polyclonal whole serum
(diluted 1:50), purified 11B1.G4 (100 m g/ml) and 11B1.G4
culture supernatant. Low but specific labelling was observed
on the plasma membrane (Fig. 4a,d) and in endosomal
structures (Fig. 4b-d). From the morphology of the labelled
structures these were identified as tubulo-vesicular early
endosomes (Fig. 4d, and inset) and late endosomes (Fig. 4b
and c). The majority of labelling was associated with the
internal vesicles of the late endosomes, however some was also
associated with the limiting membrane. Consistent with the
endocytosis of PETA-3, low levels of labelling were also seen
associated with coated pits. Negligible labelling was associated
with other cellular organelles such as the endoplasmic
reticulum, nucleus, and Golgi complex (see Fig. 4b) although
some Weibel-Palade bodies showed a low level of membrane
associated labelling (not shown).
PETA-3 associates with multiple integrins in
endothelial cells
To examine possible association of PETA-3 with other
proteins, confluent fourth passage EC monolayers were lysed
in 1% CHAPS lysis buffer and immunoprecipitated with
antibodies as indicated (Fig. 5A,B). Western blotting with anti-
PETA-3 mAb 11B1.G4 showed co-immunoprecipitation of
PETA-3 with the integrin b 3, b 4, a 2 and a 6 chains (Fig. 5A)
in addition to the previously described b 1 (Ashman et al.,
1997), a 3 (Yanez-Mo et al., 1998; Yauch et al., 1998) and a 5
(Hasegawa et al., 1998) associations. PETA-3 has a single N-
linked glycosylation site (Fitter et al., 1995) and the doublet
represents the mature, fully glycosylated form (32 kDa) and
the immature form (27 kDa) as verified by treatment with
Endoglycosidase F (data not shown). In order to assess
the specificity of PETA-3/integrin interactions, immuno-
precipitations with several other endothelial adhesion
molecules and transferrin receptor were carried out (Fig. 5A).
PETA-3 was not detected in PECAM-1, transferrin receptor,
CD34, CD44, or VE-cadherin precipitates but did co-
immunoprecipitate with the other TM4SF members CD9 and
CD63 as observed in haemopoietic cells (Fitter et al., 1999).
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Fig. 1. Characterisation of the
subcellular localisation of PETA-3
in cultured EC. (A) PETA-3
staining of formaldehyde fixed
non-permeabilised cells.
(B) Staining of PETA-3 in
permeabilised EC.
(C) Subconfluent ECs showed
strong perinuclear staining for
PETA-3. (D) Expression of CD9
was restricted to the plasma
membrane, primarily at cell
junctions in permeabilised cells.
(E) Staining for the endoplasmic
reticulum marker gp180.
(F) Wheatgerm agglutinin. Bar,
55 m m.
837Localisation and function of PETA-3
Given the hydrophobic nature of TM4SF proteins, the use
of mild detergents has been suggested to lead to artifactual
associations (Hemler et al., 1996). Therefore, co-
immunoprecipitation experiments using more stringent
conditions (1% NP-40), were carried out in parallel to the
studies performed with CHAPS (Fig. 5B). PETA-3 co-
immunoprecipitated with several integrin chains as was
observed with CHAPS lysates, however, the associations with
b 3, a 2, a 5 and the TM4SF members CD9 and CD63 were not
observed under these conditions.
Since the association of PETA-3 with the b 3, a 2 and a 5
chains was not stable in NP-40, we further investigated their
interaction with PETA-3 by re-precipitations from re-
solubilised PETA-3 immunoprecititates derived from CHAPS
lysates. Using this methodology, b 3, a 2 and a 5 integrin chains
were readily re-precipitated from PETA-3 immunoprecipitates
(Fig. 5C). Similarly, a 3 and a 6 were also detected. The lower
levels of a 3 and a 6 detected by re-precipitation may reflect the
inability of NP-40 to disrupt their interaction with PETA-3 (see
Fig. 5B). Conversely, the stronger a 2 and a 5 signals obtained
might be due to the lability of these interactions in NP-40 used
in resolubilisation. b 1 and b 4 associations were not examined
by this methodology. Re-precipitation experiments were also
carried out with mAbs to transferrin receptor, CD34, CD44,
VE-cadherin and PECAM-1, all of which failed to re-
precipitate from NP-40 solubilised 11B1.G4
immunoprecipitates (Fig. 5C). The ability of these control
mAbs to immunoprecipitate was verified from surface
biotinylated CHAPS lysates (Fig. 5D). All mAbs
immunoprecipitated substanital amounts of protein of
predicted molecular weight, with the exception of transferrin
receptor which was weak due to the majority of this antigen
residing within intracellular endosomes.
Comparison of the subcellular distribution of
integrins and PETA-3
To examine whether integrin associations with intracellular
PETA-3 might exist, the colocalisation of integrins in HUVECs
was examined by confocal microscopy. Staining of the integrin
b 1 chain was essentially identical to the localisation of PETA-
3, as both cell junctions and intracellular vesicles were labelled
by 2-colour confocal microscopy (Fig. 6A,B). Staining for b 3
(Fig. 6C) also displayed a similar morphology to that of PETA-
3. The a 2 chain showed predominantly junctional staining, as
previously reported (Fig. 6D; Lampugnani et al., 1991), whilst
a 5 (Fig. 6E) and a 6 (Fig. 6F) were similar to that of b 1, b 3
and PETA-3. Both anti-b 4 and a 3 mAbs labelled fixed EC
poorly and were not suitable for immunohistology (data not
shown).
Anti-PETA-3 mAbs inhibit EC motility
Previously, it has been demonstrated that b 1 and b 3 integrins
mediate endothelial cell migration (Leavesley et al., 1993).
Since PETA-3 associated with b 1 and b 3, and TM4SF proteins
have been proposed to modulate integrin function, we
examined the effect of anti-PETA-3 mAbs on EC migration.
Confluent EC monolayers were wounded, treated with 2-10
m g/ml mAb and the degree of cell migration assessed over 30
hours (Fig. 7). Perturbation of EC migration was analysed by
statistical analysis using 2-way analysis of variance (ANOVA).
Incubation of cells with 10 m g/ml each of isotype matched non-
binding control mAbs, or isotype matched binding control
mAbs (3D2, anti-PECAM-1 and 61-2A1, anti-E-selectin) did
not alter the rate of migration when compared to untreated ECs
(P>0.05). In contrast, anti-PETA-3 mAbs 14A2.H1 and
11B1.G4 (10 m g/ml) inhibited the migration of cells into the
wound by 32% and 41%, respectively, at 30 hours post-
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Fig. 2. Quantitation of intracellular PETA-3 by immunofluorescent
labelling of ECs in the absence and presence of the permeabilising
agent saponin and flow cytometry. Histograms represent (A) PETA-
3, (B) CD9 and (C) CD63 binding to non-permeabilised (black) or
saponin permeabilised (grey) EC. Negative control mAb binding
(dotted) is shown for comparison. Data presented are representative
histograms from quadruplicate tests. Numbers in parenthesis
represent mean fluorescent intensity of respective peaks, boldface =
saponin treatment.
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wounding when compared to negative control mAb treatments
and untreated EC (P<0.01). Treatment of ECs with 2 m g/ml of
the b 1-activating mAb 8A2, or 10 m g/ml anti-CD9 mAb
1AA2.H9 also resulted in reduced migration, 52% and 33%
inhibition at 30 hours, respectively (P<0.01). These findings
were reproduced in two separate experiments performed and
for concentrations of anti-PETA-3 mAb 11B1.G4 ranging from
1-10 m g/ml. Inhibition in response to 11B1.G4 was effective
over a range of concentrations (1-10 m g/ml), whereas lower
doses of 14A2.H1 were less effective (data not shown). To
determine whether mAb induced proliferation contributed to
the movement of cells into the wound, total protein content
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Fig. 3. Comparison of PETA-3
labelling with markers of
different subcellular
compartments. Staining for
PETA-3 shown in green with g -
adaptin, von Willebrand factor,
transferrin receptor or CD63
labelling of the same fields
shown in red. Merges of red and
green images were generated to
demonstrate colocalisation
(yellow). (A-C) Staining of the
trans-Golgi network for g -
adaptin or (D-F) Weibel-Palade
bodies with von Willebrand
factor did not colocalise with
PETA-3. (G-I) PETA-3 partially
colocalised with transferrin
receptor within the perinuclear
region. (J-L) The perinuclear
staining of PETA-3 colocalised
strongly with CD63. Bar, 55 m m.
Fig. 4. Ultrastructural localisation of PETA-3. Ultrathin frozen
sections of EC were labelled with affinity purified PETA-3
polyclonal antibody followed by 10 nm Protein A-gold. (a and b)
Low power overviews showing the general distribution of PETA-3
labelling. (a) The plasma membranes of two closely apposed cells
whereas panel b shows the juxtanuclear area of a cell. The plasma
membrane (P) and a putative late endosomal structure (L, panel b)
show significant labelling (labelling on plasma membrane
indicated by arrows in all panels; labelling in putative endosomal
structures by arrowheads). The ER surrounding the nucleus (N) as
well as the Golgi complex (G) are unlabelled. (c) A representative
image of a putative late endosome (L). (d) Labelling on the plasma
membrane (P), a coated pit (double arrowheads) and tubular
elements, typical of early endosomal or recycling endosome
tubules; inset shows a representative early endosome (E). Bars,
100 nm.
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within each well was determined at the cessation of the
experiment. No significant change in total protein was
observed for any of the treatments (data not shown).
Anti-PETA-3 mAbs inhibit in vitro capillary formation
Treatment of EC with the activating b 1 mAb 8A2 has been
previously shown to inhibit in vitro angiogenesis as assessed
by capillary tube formation in Matrigel (Gamble et al., 1993).
To investigate whether PETA-3 modulates this process
(possibly through its association with b 1 or other integrins),
the effect of anti-PETA-3 mAb on in vitro tube formation was
investigated. EC cultured on Matrigel in the presence of 1-10
m g/ml anti-PETA-3 mAbs showed retarded tube formation
(Fig. 8) in three separate experiments performed. Although not
as effective as mAb 8A2, anti-PETA-3 mAbs significantly
altered tube formation when compared to untreated, binding or
non-binding negative control mAbs. Table 1 shows the pooled
data from three experiments and statistical analysis was
performed on these pooled data. At the 10 hour time point,
treatment with 8A2 showed a statistically significant decrease
(P<0.05) in tube length and increase in tube number when
compared to controls. Although the anti-PETA-3 mAbs
11B1.G4 and 14A2.H1 (1-10 m g/ml) showed similar results at
10 hours, only the increase in the number of tubes in 11B1.G4
treated EC was statistically significant (P<0.05) at this time
point when compared to controls. However, at 20 hours both
the decrease in tube length and the number of tubes formed
were significantly altered by both anti-PETA-3 mAbs as well
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Fig. 5. Co-immunoprecipitation of PETA-3 with multiple
integrins. Western blotting for PETA-3 showed co-
precipitation with integrins and TM4SF members from EC
lysates prepared with (A) 1% CHAPS and (B) 1% NP-40.
(C) EC were surface biotinylated and lysed in 1% CHAPS.
Immunoprecipitations with the anti-PETA-3 mAb
11B1.G4 were carried out and followed by resolubilisation
of immunoprecipitates in NP-40/0.2% SDS. Re-
precipitations from NP-40 solubilised 11B1.G4
immunoprecipitates were then performed, separated by
PAGE and detected by straptavidin-alkaline phosphatase as
described. (D) Control mAbs used for co-
immunoprecipitation experiments were verified by
immunoprecipitation from surface biotinylated CHAPS
lysates.
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as mAb 8A2 when compared to controls. The anti-CD9 mAb
1AA2.H9 failed to modulate tube formation.
DISCUSSION
PETA-3 is localised to the endocytic pathway
Cell surface PETA-3 is predominately localised to EC
junctions in a similar manner to CD9, as has been described
(Yanez-Mo et al., 1998). However, the data presented here
show that the majority of this protein is intracellular (like
CD63). Thus unlike CD9 and CD63, PETA-3 does not appear
to be restricted to a single subcellular compartment.
Furthermore, while the carboxyl-terminal cytoplasmic tail of
CD63 contains a putative lysosomal targeting motif (Metzelaar
et al., 1991), the domains of PETA-3 responsible for
intracellular and plasma membrane targeting remain undefined.
The morphology of PETA-3 staining did not resemble the
endoplasmic reticulum marker gp180 or the Golgi marker, g -
adaptin (Robinson and Pearse, 1986). Furthermore, the
localisation of PETA-3 was not sensitive to treatment with
brefeldin A which disrupts the Golgi. These data, together with
the observation that the majority of PETA-3 is fully
glycosylated and showed co-localisation with WGA, imply
that this molecule predominantly resides within a post-Golgi
compartment. Based on colocalisation studies using transferrin
receptor and CD63 mAbs and labelling of PETA-3 by immuno-
electron microscopy, we conclude that the majority of
intracellular PETA-3 is associated with endosomes, late
endosomes and/or lysosomes. Also, like the recycling mannose
6-phosphate receptor in late endosomes (Griffiths et al., 1988),
PETA-3 was mostly present on internal membranes of these
structures.
The labelling of clathrin coated pits and vesicles suggests
that PETA-3 is internalised from the plasma membrane.
Additionally, localisation in tubular vesicular elements of early
endosomes, and the colocalisation with perinuclear transferrin
receptor, which is predominantly associated with the
perinuclear recycling vesicle, imply recycling of cell surface
PETA-3 via the endocytic pathway. Perhaps PETA-3 is
involved in the fusion of cellular membranes, in particular
vesicles within the endocytic pathway or it might be involved
in protein-protein interactions mediating internalisation and/or
sorting events.
PETA-3 associates with multiple integrins
Association of PETA-3 with integrins and the two TM4SF
members CD9 and CD63 was demonstrated by co-
immunoprecipitation under mild lysis conditions. Precipitation
from CHAPS lysates using mAbs to the various a chains and
blotting for PETA-3 showed association with b 1, b 3, b 4, a 2,
Fig. 6. The subcellular
localisation of integrins
resembles PETA-3 in EC. EC
were labelled by indirect
immunofluorescence and
examined by 2-colour confocal
microscopy. (A) PETA-3 and
(B) b 1 integrin labelling of the
same field. For comparison,
labelling of (C) b 3, (D) a 2,
(E) a 5 and (F) a 6 are also
shown. Bar, 55 m m.
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Fig. 7. Anti-PETA-3 mAbs inhibit EC motility. EC monolayers were
scraped and the rate of cell migration into the ‘wound’ was assessed
over 30 hours. Data points represent the mean ± s.e.m. of 30
measurements. (h) 11B1.G4 (10 m g/ml), (j) 14A2.H1 (10 m g/ml),
(n) 1AA2.H9 (10 m g/ml), (m) 8A2 (2 m g/ml). (s, solid line)
Untreated, (d) isotype matched non-binding control mAbs (10
m g/ml), (s, broken line) isotype matched binding mAb 3D2 (anti-
PECAM-1; 10 m g/ml), EC migration in the presence of 10 m g/ml
mAb was analysed by 2-way ANOVA. *P<0.01 when compared to
untreated, isotype matched binding and non-binding controls.
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a 3, a 5 and a 6 integrin chains. In addition, when surface-
biotinylated cells were subjected to mild detergent lysis,
immunoprecipitation with PETA-3 mAb, solubilisation of the
precipitates in stronger detergent and re-precipitation with
mAbs to integrin chains, we were able to specifically examine
PETA-3/integrin complexes at the cell surface. Using this
protocol, surface association with all integrins examined could
be demonstrated. The PETA-3/integrin and PETA-3/CD63
associations reported in this study add to the initial
characterisation of PETA-3 associations with b 1 integrins and
CD81 (Ashman et al., 1997; Yanez-Mo et al., 1998; Yauch et
al., 1998; Hasegawa et al., 1998).
Apart from the ‘classical’ complexes of TM4SF members
with a 3b 1, a 4b 1 and a 6b 1 (reviewed by Hemler et al., 1996;
Maecker et al., 1997), associations with the b 3, b 4, a 2 and a 5
integrin chains observed in this study have been less widely
reported. As b 4 only associates with a 6, we conclude that
PETA-3 associates with the a 6b 4 complex. Similarly b 3 in EC
is paired with a v, and although co-immunoprecipitation with
a v was not investigated due to the lack of a suitable antibody,
the data suggest that PETA-3 complexes with a vb 3. Other
TM4SF proteins have also been shown to associate with non-
b 1 integrin sub-families, including CD9 with a IIbb 3 and a 4b 7
and CD63 with a Lb 2 (Slupsky et al., 1989; Mannion et al.,
1996; Skubitz et al., 1996). Despite the promiscuous
association of PETA-3 with integrins observed in this study,
the lack of co-immunoprecipitation with other EC adhesion
molecules and transferrin receptor demonstrates the specificity
of the reported interactions. Furthermore, several of the PETA-
3/integrin associations were NP-40 stable. Therefore we
conclude that PETA-3 associates with a wide range of integrins
including members of the b 1, b 3 and b 4 sub-families, thus
extending the range of known TM4SF/integrin associations.
Additionally, we have observed association of PETA-3 with
CD9 and CD63 in EC. In contrast to the results with certain
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Fig. 8. Anti-PETA-3 mAbs modulate the formation of
capillaries in vitro. EC were plated onto Matrigel at
2.5· 104/well in the presence or absence of mAbs as indicated.
Treatment with anti-PETA-3 mAb 11B1.G4 (10 m g/ml) or b 1
mAb 8A2 (2 m g/ml) resulted in more tubes of shorter length.
Data shown are representative photographs of one of three
separate experiments. Bar, 800 m m.
Table 1. Anti-PETA-3 mAbs 11B1.G4 and 14A2.H1
modulate in vitro capillary formation
10 hours 20 hours
Length Length
Treatment (m m) Number ( m m) Number
Untreated 408±46 11.0±0.5 537±68 22.5±1.4
3D3.3+1D4.5 (Control) 374±16 12.6±2.7 473±46 26.0±1.6
3D2 (PECAM-1) 441±57 12.1±3.1 560±45 22.4±2.4
61-2A1 (E-selectin) 430±63 9.3±1.5 561±56 21.8±2.4
1AA2.H9 (CD9) 423±23 9.7±1.6 466±65 24.6±4.7
11B1.G4 (PETA-3) 344±33 24.3±1.3* 364±24* 33.9±3.0*
14A2.H1 (PETA-3) 374±14 10.7±1.6 386±29* 31.3±2.2*
8A2 (b 1) 221±7* 175.8±40.1* 260±23* 126.1±17.7*
Anti-PETA-3 mAbs modulate in vitro capillary formation resulting in more
tubes of shorter length. Results presented are the means ± s.e.m. of pooled
data from three assays performed in duplicate (see Fig. 8). t-tests were
performed to compare each mAb treatment with untreated and isotype
matched non-binding controls, *P<0.05.
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integrins, the association of PETA-3 with CD9 and CD63 was
not detected when cells were lysed using 1% NP-40. Others
have also reported loss of TM4SF/TM4SF and TM4SF/integrin
associations in detergents which disrupt hydrophobic
interactions (Fitter et al., 1999; Mannion et al., 1996).
Anti-PETA-3 antibodies modulate EC function
The data presented here demonstrate inhibition of EC
migration in wounded monolayers by anti-PETA-3 mAbs. In
some cases, anti-integrin mAbs reverse the effects of anti-
TM4SF mAbs on adhesion and migration (Masellis-Smith and
Shaw 1994; Shaw et al., 1995; Behr and Schriever 1995). Thus
the functional responses induced by anti-TM4SF mAbs may
be mediated indirectly. Since EC motility is inhibited by anti-
b 1 and b 3 antibodies (Leavesley et al., 1993) and PETA-3
associates with these integrins, we postulate that the effects of
anti-PETA-3 mAbs on EC migration are due to modulation of
integrin function. The effect of anti-PETA-3 mAbs on EC
motility has recently been reported by other investigators
(Yanez-Mo et al., 1998) and was attributed to the association
of PETA-3 with a 3b 1 integrin, since these mAbs caused a
small but statistically significant increase in adhesion to
fibronectin, type I collagen and laminin. Although modulation
of integrin affinity has been demonstrated by the direct binding
of anti-b 1 mAbs such as 8A2 and QE2.E5 (Kovach et al., 1992;
Faull et al., 1996), other studies to date have failed to
demonstrate altered adhesion of cells to ECM after stimulation
by anti-TM4SF mAbs (Mannion et al., 1996; Fitter et al.,
1999).
We have also demonstrated modulation of in vitro capillary
tube formation on the complex matrix Matrigel, by anti-PETA-
3 mAbs. This process involves EC movement, realignment to
form sprouts and subsequent fusion and extension to form
mature capillary tubes (Gamble et al., 1993). mAbs against a 6
and b 1 integrins block endothelial tube formation on Matrigel,
thus demonstrating a major role for a 6b 1 in this process (Davis
and Camarillo, 1995). Although the mechanism of altered tube
formation by anti-PETA-3 mAbs remains undefined, it does not
solely correlate with decreased cellular motility, as treatment
of EC with anti-CD9 mAb which also retarded EC migration,
did not influence tube formation. In contrast to cell migration
and tube formation, no detectable effect on neutrophil trans-
endothelial migration was observed when EC were treated with
F(ab¢ )2 fragments of anti-PETA-3 mAbs under previously
established conditions (Cooper et al., 1995; and data not
shown). Therefore PETA-3 does not appear to be involved in
leukocyte recognition of endothelial cells or the
transendothelial migratory process.
PETA-3, integrins and endocytosis: a functional
link?
Endocytosis and subsequent recycling of integrins to the
leading edge promotes cell migration (reviewed by
Lauffenberger and Horwitz, 1996). Recycling of a 5b 1, a vb 3
and a 6b 4, which all associate with PETA-3, has been
described (Bretscher, 1992; Sczekan and Juliano, 1990; Panetti
and McKeown-Longo, 1993; Bretscher, 1989; Raub and
Kuentzel, 1989). However, the mechanism by which integrins
are internalised, sorted and recycled to the leading edge of
migrating cells remains unclear. The similar intracellular
localisation of PETA-3 and integrins suggests that PETA-3
may enter the endocytic pathway complexed with these
molecules. Interestingly, internalisation of PETA-3/integrin
complexes appears to be selective as CD9, which is also
present in integrin complexes on the plasma membrane, was
not detected within the endocytic pathway. Therefore we
propose that PETA-3 may play a specific role in the
internalisation and recycling of integrin complexes through the
endocytic pathway. Furthermore, the functional effects of anti-
PETA-3 antibodies may be due to disruption of integrin
turnover.
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